Global burden of blood-pressure-related disease, 2001

Lawes, Carlene M.M.; Hoorn, Stephen Vander; Rodgers, Anthony

doi:10.1016/s0140-6736(08)60655-8

Cited by 1,991 publications

(1,153 citation statements)

References 26 publications

Supporting

Mentioning

1,100

Contrasting

Unclassified

Order By: Relevance

“…Hypertension and associated cardiovascular diseases are a global health burden with increasing prevalence across all continents [14–16]. Hypertension is in many cases asymptomatic and awareness of the condition is therefore limited until organ damage, such as stroke, myocardial infarction, or heart failure occur.…”

Section: Introductionmentioning

confidence: 99%

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Delles

Carrick

Graham

et al. 2018

Expert Review of Proteomics

View full text Add to dashboard Cite

Introduction: Hypertension is a complex and multifactorial cardiovascular disorder. With different mechanisms contributing to a different extent to an individual’s blood pressure, the discovery of novel pathogenetic principles of hypertension is challenging. However, there is an urgent and unmet clinical need to improve prevention, detection, and therapy of hypertension in order to reduce the global burden associated with hypertension-related cardiovascular diseases.Areas covered: Proteomic techniques have been applied in reductionist experimental models including angiotensin II infusion models in rodents and the spontaneously hypertensive rat in order to unravel mechanisms involved in blood pressure control and end organ damage. In humans proteomic studies mainly focus on prediction and detection of organ damage, particularly of heart failure and renal disease. While there are only few proteomic studies specifically addressing human primary hypertension, there are more data available in hypertensive disorders in pregnancy, such as preeclampsia. We will review these studies and discuss implications of proteomics on precision medicine approaches.Expert commentary: Despite the potential of proteomic studies in hypertension there has been moderate progress in this area of research. Standardized large-scale studies are required in order to make best use of the potential that proteomics offers in hypertension and other cardiovascular diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Delles

Carrick

Graham

et al. 2018

Expert Review of Proteomics

View full text Add to dashboard Cite

show abstract

“…Almost 77% of strokes are first attacks; therefore, primary prevention is of great importance 2. Hypertension is the most treatable and prevalent risk factor for stroke 3, 4. It affects >1 billion people around the world 5.…”

Section: Introductionmentioning

confidence: 99%

China Stroke Primary Prevention Trial: Visit‐to‐Visit Systolic Blood Pressure Variability Is an Independent Predictor of Primary Stroke in Hypertensive Patients

Men

Sun

Fan

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundThe optimal range of blood pressure variability remains unclear. We aimed to stratify the degree of risk of stroke based on visit‐to‐visit systolic blood pressure (SBP) variability in a large Chinese hypertensive population in 32 communities.Methods and ResultsWe retrospectively analyzed the data of 20 702 hypertensive patients from the China Stroke Primary Prevention Trial. The participants were randomized into 2 treatment groups to receive either enalapril or enalapril plus folic acid. Their blood pressures were measured every 3 months. The outcome was the first stroke. Three parameters of SBP variability were calculated: standard deviation, coefficient of variation, and average real variability. The records of first 4, 6, 8, 10 and 12 visits at which SBP was measured were used to calculate SBP variability and to predict subsequent stroke risk in adjusted Cox regression models. After median follow‐up of 4.5 years, 597 patients had experienced stroke. Visit‐to‐visit SBP variability was an independent predictor of subsequent stroke (eg, the hazard ratio for the highest quintile of average real variability [22.67–61.07 mm Hg] over 6 visits was 1.55, 95% CI 1.07–2.25, P=0.021), independent of mean SBP over the follow‐up period. Its value was more predictive when more blood pressure records were used.ConclusionsVisit‐to‐visit SBP variability is an independent predictor of primary stroke in Chinese hypertensive patients. This predictive value depends on the number of blood pressure measurements used to calculate variability but is independent of mean SBP.Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.

show abstract

“…2 Beyond mortality, hypertension is a significant risk factor for CV morbidity, including stroke, myocardial infarction, heart failure, and renal failure. 3 These events occur at higher rates in individuals with apparent treatment-resistant hypertension (aTRH) 4 and in individuals with chronic kidney disease (CKD). aTRH is particularly prevalent in patients with CKD.…”

Section: Introductionmentioning

confidence: 99%

Apparent Treatment-Resistant Hypertension and Chronic Kidney Disease: Another Cardiovascular-Renal Syndrome?

Vemulapalli

Tyson

Svetkey

2014

Advances in Chronic Kidney Disease

View full text Add to dashboard Cite

To identify patients at increased risk of cardiovascular (CV) outcomes, apparent treatment-resistant hypertension (aTRH) is defined as having a blood pressure above goal despite the use of 3 or more antihypertensive therapies of different classes at maximally tolerated doses, ideally including a diuretic. Recent epidemiologic studies in selected populations estimated the prevalence of aTRH as 10% to 15% among patients with hypertension and that aTRH is associated with elevated risk of CV and renal outcomes. Additionally, aTRH and CKD are associated. Although the pathogenesis of aTRH is multifactorial, the kidney is believed to play a significant role. Increased volume expansion, aldosterone concentration, mineralocorticoid receptor activity, arterial stiffness, and sympathetic nervous system activity are central to the pathogenesis of aTRH and are targets of therapies. Although diuretics form the basis of therapy in aTRH, pathophysiologic and clinical data suggest an important role for aldosterone antagonism. Interventional techniques, such as renal denervation and carotid baroreceptor activation, modulate the sympathetic nervous system and are currently in phase III trials for the treatment of aTRH. These technologies are as yet unproven and have not been investigated in relationship to CV outcomes or in patients with CKD.

show abstract

Global burden of blood-pressure-related disease, 2001

Cited by 1,991 publications

References 26 publications

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

China Stroke Primary Prevention Trial: Visit‐to‐Visit Systolic Blood Pressure Variability Is an Independent Predictor of Primary Stroke in Hypertensive Patients

Apparent Treatment-Resistant Hypertension and Chronic Kidney Disease: Another Cardiovascular-Renal Syndrome?

Contact Info

Product

Resources

About